A new protocol reduces median door-to-needle time to the benchmark of 30 minutes in acute stroke treatment

Neurologia (Engl Ed). 2021 Sep;36(7):487-494. doi: 10.1016/j.nrleng.2018.03.009. Epub 2020 Mar 18.

Abstract

Introduction: Recent analyses emphasise that The Benchmark Stroke Door-to-Needle Time (DNT) should be 30min. This study aimed to determine if a new in-hospital IVT protocol is effective in reducing door-to-needle time and correcting previously identified factors associated with delays.

Material and methods: In 2014, we gradually introduced a series of measures aimed to reduce door-to-needle time for patients receiving IVT, and compared it before (2009-2012) and after (2014-2017) the new protocol was introduced.

Results: The sample included 239 patients before and 222 after the introduction of the protocol. Median overall door-to-needle time was 27min after the protocol was fully implemented (a 48% reduction on previous door-to-needle time [52min], P<.001)]. Median door-to-needle time was lower when pre-hospital code stroke was activated (22min). We observed a 26-min reduction in the median time from onset to treatment (P<.001). After the protocol was implemented, the "3-hour-effect" did not affect door-to-needle time (P=.98). Computed tomography angiography studies performed before IVT were associated with increased door-to-needle time (P<.001); however, the test was performed after IVT was started in most cases.

Conclusions: Hospital reorganisation and multidisciplinary collaboration brought median door-to-needle time below 30min and corrected previously identified delay factors. Furthermore, overall time from onset to treatment was also reduced and more stroke patients were treated within 90min of symptom onset.

Keywords: Acute stroke; Door-to-needle time; Ictus agudo; Ictus isquémico; In-hospital protocols; Intravenous thrombolysis; Ischaemic stroke; Protocolo intrahospitalario; Stroke treatment; Tiempo puerta-aguja; Tratamiento del ictus; Trombolisis intravenosa.

MeSH terms

  • Benchmarking*
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Stroke* / drug therapy
  • Thrombolytic Therapy
  • Time-to-Treatment

Substances

  • Fibrinolytic Agents